Home | Medical-Newswire.Com:
(Medical-NewsWire.com, September 20, 2012 ) New York, NY -- Advanced Medical Isotope Corporation (ADMD) is already a US-based manufacturer and distributor of medical isotopes and is also developing key technologies that may offer a superior alternative to the current standard of care for battling cancer with nuclear medicine.
In a Thursday report, VFC's Stock House, an information and research outlet that brings ideas and opens discussions to a broad spectrum of investors, identifies key point for optimism regarding the company and examines its speculative potential as an investment. Full report available at: http://vfcsstockhouse.com/blog/article/-advanced-medical-isotope-corporation-expanded-distribution-and-radiogel-technology-hold-the-keys-to-the-future
Advanced Medical Isotope Corporation (ADMD) has - through key partnerships, expanding distribution channels and the acquisition of a license to a novel cancer-fighting technology - well positioned itself to become a growth player in the field of nuclear medicine, specifically in the field of the production and distribution of medical isotopes. Medical isotopes are used in molecular imaging, therapy, and nuclear medicine to diagnose, manage and treat diseases and are deemed a hot item whenever discussed because of the geopolitical implications of non-nuclear nations attempt to enrich uranium for - ahem - solely medical purposes.
Advanced Medical is one of only a few companies in the United States manufacturing and distributing such isotopes and it's likely that business could quickly hit a growth spurt - not only through the company's own indigenous expansion and distribution efforts, but also because of the growing desire of the medical community in the US to use 'home grown' nuclear materials, not to mention increasing regulation that may force the community to do so anyway.
AMIC already offers a broad variety of isotopes and, as outlined in a recent quarterly report, is looking to expand its 'pipeline' of product offerings for its distribution network of customers that include - but is not limited to - national laboratories, hospitals, research facilities and universities.
Many of the company's isotopes are put to use through molecular imaging, or Positron Emission Tomography (PET), which enables Doctors and medical professionals to identify cancerous condictions well before detection means that search for tumor mass. Some of the radiopharmaceutical products based on the medical isotopes are also used in the early detection of certain cardiovascular indications and, as mentioned above, the demand for such products is growing, not shrinking. According to numbers identified in a recent company presentation and credited to the World Nuclear Association, the use of medical isotopes is growing at an annual rate of 10%.
That places AMIC right in the middle of a potential growth boom.
While production and distribution may encompass the company's core business model, AMIC is moving heavily into the field of treatment, too. The process of placing radioactive "seeds" in or near a cancerous tumor is known as brachytherapy, and AMIC is developing a pipeline based on such technology to augment the already-growing core business plan.
In April, the company acquired a license and numerous relating patents to an injectible radiogel technology that could have a significant impact on the next generation of fighting cancer. Using the radiogel technology doctors could deliver Yttrium-90 "microspheres" directly into cancerous tissue. Because the injectible polymer turns solid and holds the microspheres in place, there is little to no threat of any radiation escaping and damaging surrounding tissue. As described by Dr. Alan Walter, Chair of the AMIC Scientific Committee, in a presentation available on the company's home page, such a technology could be termed as using "smart bullets" to target cancerous cells.
Yttrium-90, in the form of Polymer seeds, is an already-established medical isotope with numerous applications in existing cancer treatment and has demonstrated effectiveness in combating head, neck, liver and prostate cancers, according to an above-linked company presentation. The radiogel application of Yttrium-90 could potentially 'storm the scene' in treating numerous cancer types with the intent of targeting those tumors in the hard-to-get to areas of the body that eliminates surgery as an option.
Both the Polymer seeds and the acquired the radiogel technology significantly boost the diversity of AMIC, offering a targeted path to enter the realm of caner treatment to augment the production, sales and distribution channels of its isotopes.
It's possible, based on previous expectations, that the Brachytherapy pipeline could hit market within a couple of years. At that point AMIC could either move forward with commercialization on its own or out-license the technology to someone else and use that revenue stream of royalties to fund the expansion of the core business.
Shares were up by eight percent on Wednesday, although volume was very light. That said, volume has been picking up significantly over the past few months and has tripled already once this year. Volume has also stormed in after the company's more relevant press releases, indicating that there are investors on the sidelines who either wait to play a quick trade or may be taking a 'wait and see' approach to playing this still-speculative stock.
Should the potential of the AMIC distribution network continue to expand and meet the growing demand for nuclear medicine - and should the polymer seeds and radiogel technology also hit market with momentum - then it's likely that the current ADMD share price could start to move. Currently, shares consistently trade for a few pennies above the twenty cents mark, give or take.
Based on the potential of the developing technology, already-available products and future product offerings, the current ADMD trading levels could serve as an opportune accumulation period to those looking at the risk/reward profile for the future. The current market cap of still under twenty million indicates that many investors are still unconvinced, but when searching for potential payoff picks on the bulletin board stocks, it pays off to be in while the stock is still moving along relatively unnoticed, as the best percentage gains to be had in any run start with being in place before the run starts.
That said, the stock market is risky business and there are no sure things, that's why it's up to each investor to conduct his or her own DD and invest accordingly.
Still a developing story worth monitoring.
Disclosure: No position.
Follow ADMD developments and other small cap stocks at VFCsStockHouse.com
Contact VFC's Stock House: firstname.lastname@example.org
Follow VFC's Stock House on Twitter: https://twitter.com/#!/VFCsStockHouse
'Like' VFC's Stock House on Facebook: http://www.facebook.com/pages/VFCs-Stock-House/143724412345213
VFC's Stock House is an information and research outlet that brings new ideas to the table and opens discussions for a broad spectrum of investors, with a strong focus on - but not limited to - biotech stocks, biopharma stocks, and pharmaceutical and healthcare stocks. VFC's Stock House provides individual company profiles, write-ups and reports as well as giving general insights and opinions into broader-market news. At the conclusion of most weeks, VFC's Stock House issues a "Weekly Stock Watch" that examines news items, stocks and stories that made headlines during the previous trading week, but may also make headlines or influence trends during the upcoming week as well. The information contained within the pages of VFC’s Stock House are not intended to be taken as advice, but as a starting point where investors can follow up with their own DD and make informed and well thought-out investment decisions. For full disclaimer visit: http://vfcsstockhouse.com
VFC's Stock House
Health News Headlines - Yahoo! News
Get the latest health news headlines from Yahoo! News. Find breaking health news, including analysis and opinion on
top health stories.
Health care debate has trust, politics themes, too
9 Dec 2013 at 12:21pm
WASHINGTON (AP) ? For months, the talk was all about computer code. About response times. About glitches and bugs.
Uruguay to approve pot dealing, despite risks
9 Dec 2013 at 11:34am
MONTEVIDEO, Uruguay (AP) ? Uruguay is pushing ahead to create a legal marijuana market despite warnings from educators, psychiatrists and pharmacists of dangerous side effects.
APNewsBreak: Feds balk at paper health application
7 Dec 2013 at 9:00am
FORT LAUDERDALE, Fla. (AP) ? Federal health officials, after encouraging alternate sign-up methods amid the fumbled rollout of their online insurance website, began quietly urging counselors around the country this week to stop using paper applications to enroll people in health insurance because of concerns those applications would not be processed in time.
High response rates seen with oral Takeda myeloma drug: study
9 Dec 2013 at 12:47pm
Most newly diagnosed patients with the blood cancer multiple myeloma had a very strong response to an experimental oral drug being developed by Takeda Pharmaceutical Co when given in combination with standard treatments, according to data from a study presented on Monday. Overall, 94 percent of the 62 patients in the Phase I/II trial had their cancer respond to Takeda's MLN9708 taken twice a week in combination with Celgene Corp's Revlimid and the corticosteroid dexamethasone. The rate of those who had either a complete response or very good partial response was an impressive 76 percent, researchers said.
A Walk in the Woods
9 Dec 2013 at 12:36pm
Sometimes there's only one thing that works to bring sanity back into my life, energy back into my soul, and balance back into my body--and that is a walk in the woods. It doesn't have to be a perfect day or the right season, because it's not about being entertained or impressed. It's about finding and re-finding peacefulness and focus. It's about regenerating my soul. This past weekend was just such a time. I was well rested and well fed and not too stressed out about anything in particular, but I just couldn't seem to find my focus. My
The 5 Key Emotions of Success
9 Dec 2013 at 12:34pm
Once you've succeeded at something you know what you're doing. What was once a struggle in the learning process becomes a graceful implementation. Why graceful? Because you've become confident in your ability to deal with what life brings you.
US high court leaves intact $142 million verdict against Pfizer
9 Dec 2013 at 12:29pm
By Lawrence Hurley WASHINGTON (Reuters) - The U.S. Supreme Court on Monday left intact a $142 million jury verdict against Pfizer Inc over the marketing of the epilepsy drug Neurontin. In 2010, the jury in Massachusetts found that due to Pfizer's marketing of the drug for off-label uses, Kaiser Foundation Health Plan Inc, one of the nation's largest health maintenance organizations, and affiliates were damaged because they paid for prescriptions relating to conditions Neurontin did not effectively treat. The Supreme Court's refusal to hear Pfizer's appeal means similar claims brought against the company by insurer Aetna Inc and Harden Manufacturing Corp can also go forward.
Dealing With the December Dilemma
9 Dec 2013 at 12:29pm
Christmas and Kwanzaa are just days away, Hanukkah has just ended, and as always, for many people the issue of interfaith relationships still poses a conflict and end up fighting over what to do and where to spend the holidays. If you're fighting over this issue, that tells me three things: 1) poor communication 2) neither person is having their needs met 3) each has some fiery passion that potentially could be used in a much better way. Be open-minded, be flexible, and willing to compromise. If one person agrees to forgo his/her holiday just to avoid conflict, then resentment
Novo Nordisk gets final EU approval for haemophilia drug
9 Dec 2013 at 12:22pm
Novo Nordisk received European Union marketing authorization for its hemophilia drug NovoEight on November 13 2013, the Danish pharmaceutical company said on Monday. The world's biggest insulin producer confirmed that the European Medicines Agency (EMA) approved its marketing application after it had received a recommendation from the Committee for Medicinal Products for Human Use on September 20. The approval appeared from EMA's assessment report for NovoEight, which was published on Monday. The total market for the class of hemophilia drugs NovoEight belongs to, factor 8, is worth between 35 billion and 40 billion Danish crowns ($6.44-7.36 billion), Novo said in September.
Zen and the Art of Alzheimer's
9 Dec 2013 at 12:04pm
I expect to introduce myself repeatedly to my father this Christmas. I only hope that each time I do, he finds that he is pleased to meet me.
Pope calls hunger 'global scandal,' urges lifestyle changes
9 Dec 2013 at 12:01pm
Pope Francis denounced the "global scandal" of hunger on Monday, calling for an international "wave of prayer" to bring attention to the plight of the needy and homeless. Since his election in March, Francis, the former Cardinal Jorge Mario Bergoglio of Argentina, has frequently beseeched global leaders to fight poverty and growing inequality. "We are in front of a global scandal of around one billion - one billion people who still suffer from hunger today," he said in a video message launching a campaign by Caritas Internationalis, a confederation of 164 Catholic charities working in 200 countries.
How Technology Speeds Up Time (And How To Slow It Down Again)
9 Dec 2013 at 11:56am
It often feels as though time speeds up as we age, with each season and year seemingly passing by more quickly than the last. And according to some psychologists, in addition to aging, the way we interact with technology could also have a profound effect on the way we experience time. Sitting in front of computers all day, we're constantly confronted by a clock telling us what time it is, and it's no different whether we're at home or on the go: 60 percent of Gen Yers (ages 18-30) find themselves compulsively or subconsciously checking their smart phones for emails,
Princeton starts mass meningitis B vaccinations
9 Dec 2013 at 11:53am
PRINCETON, N.J. (AP) ? Princeton University has begun vaccinating nearly 6,000 students to try to stop an outbreak of type B meningitis in an unusual federal government-endorsed administration of a drug not generally approved for use in the United States.
Merck agrees to settle litigation over Fosamax jaw injuries
9 Dec 2013 at 11:47am
Merck & Co has agreed to settle hundreds of lawsuits over jaw injuries allegedly caused by the osteoporosis drug Fosamax, lawyers disclosed at a court hearing Monday. Lawyers for Merck and plaintiffs pursuing litigation over the once-blockbuster drug revealed at a court hearing in New York that a proposed deal had been reached to resolve 1,140 lawsuits pending in federal and state courts. Terms were not disclosed at the hearing before U.S. District Judge John Keenan, who has presided over federal litigation by plaintiffs claiming they developed osteonecrosis of the jaw from Fosamax.
How to Be More Grateful by Changing One Word
9 Dec 2013 at 11:32am
I think it's important to remind yourself that the things you do each day are not burdens, they are opportunities. So often, the things we view as work are actually the reward. Embrace your constraints. Fall in love with boredom. Do the work.